Observational analysis finds 96% cure rate with pretomanid in combination therapies for drug-resistant TB, highlighting the urgent need for widespread accessibility.
Key Points
Pretomanid, when combined with bedaquiline and linezolid, can cure 96% of drug-resistant TB cases.
The use of pretomanid significantly boosts survival rates and reduces treatment length and costs.
Recommendations include increasing access to pretomanid as part of TB treatment protocols across Pakistan.
Effective management of drug-resistant TB can ease the strain on the healthcare system in Pakistan.